Review

*Author for correspondence: Tel.: +39 080 5442231;

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy

Search for more papers by this author

Mauro Niso

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy

Search for more papers by this author

Francesco Berardi

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, I-70125 Bari, Italy

Search for more papers by this author

Published Online:3 Jul 2018https://doi.org/10.4155/fmc-2018-0072

View article

Abstract

Identification of sigma-2 receptor (sig-2R) has been controversial. Nevertheless, interest in sig-2R is high for its overexpression in tumors and potentials in oncology. Additionally, sig-2R antagonists inhibit Aβ binding at neurons, blocking the cognitive impairments of Alzheimer's disease. The most representative classes of sig-2R ligands are herein treated with focus on compounds that served to study sig-2R biology and to produce sig-2R: fluorescent ligands; multifunctional anticancer agents; and targeting nanoparticles. Although fluorescent ligands serve as ‘green’ pharmacological tools, sig-2R-multifunctional conjugates and sig-2R-targeted nanoparticles show how sig-2R targeting increases the activity of anticancer drugs in tumors with reduced toxicity. Altogether, this review draws a picture of the multiple approaches of sig-2R ligands in cancer therapy and as Alzheimer's disease modifying disease agents.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Martin WR, Eades CE, Thompson JA, Huppler RE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517–532 (1976). •• This work is the starting point of Sigma-2 receptors’ (sig-Rs) story.Medline, CAS, Google Scholar
2 Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 527, 244–253 (1990).Crossref, Medline, CAS, Google Scholar
3 Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268, 9–18 (1994).Crossref, Medline, CAS, Google Scholar
4 Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl Acad. Sci. USA 93, 8072–8077 (1996).Crossref, Medline, CAS, Google Scholar
5 Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human σ1 receptor. Nature 532, 527–530 (2016).Crossref, Medline, CAS, Google Scholar
6 Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131, 596–610 (2007).Crossref, Medline, CAS, Google Scholar
7 Cobos EJ, Entrena JM, Nieto FR, Cendan CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr. Neuropharmacol. 6, 344–366 (2008).Crossref, Medline, CAS, Google Scholar
8 Wheeler KT, Wang LM, Wallen CA et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br. J. Cancer 82, 1223–1232 (2000).Crossref, Medline, CAS, Google Scholar
9 Hornick JR, Vangveravong S, Spitzer D et al. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J. Exp. Clin. Cancer Res. 31, 41 (2012).Crossref, Medline, CAS, Google Scholar
10 Zeng C, Rothfuss J, Zhan J et al. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br. J. Cancer 106, 693–701 (2012).Crossref, Medline, CAS, Google Scholar
11 Mir SU, Schwarze SR, Jin L et al. Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy 9, 1566–1578 (2013).Crossref, Medline, CAS, Google Scholar
12 Niso M, Abate C, Contino M et al. Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity. ChemMedChem 8, 2026–2035 (2013).Crossref, Medline, CAS, Google Scholar
13 Colabufo NA, Berardi F, Abate C, Contino M, Niso M, Perrone R. Is the σ2 receptor a histone binding protein? J. Med. Chem. 49, 4153–4158 (2006).Crossref, Medline, CAS, Google Scholar
14 Abate C, Elenewski J, Niso M et al. Interaction of the σ2 receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer. ChemMedChem 5, 268–273 (2010).Crossref, Medline, CAS, Google Scholar
15 Colabufo NA, Abate C, Contino M et al. Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization. Bioorg. Med. Chem. Lett. 18, 2183–2187 (2008).Crossref, Medline, CAS, Google Scholar
16 Xu J, Zeng C, Chu W et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380 (2011). • Although sig-2R and progesterone receptor membrane component 1 were later found to be different, this work rejuvenated the interest in sig-2R prompting further studies.Crossref, Medline, Google Scholar
17 Peluso JJ, Liu X, Gawkowska A, Lodde V, Wu CA. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol. Cell Endocrinol. 320, 153–161 (2010).Crossref, Medline, CAS, Google Scholar
18 Ahmed IS, Rohe HJ, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity. J. Biol. Chem. 285, 24775–24782 (2010).Crossref, Medline, CAS, Google Scholar
19 Ahmed IS, Rohe HJ, Twist KE, Mattingly MN, Craven RJ. Progesterone receptor membrane component 1 (PGRMC1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J. Pharmacol. Exp. Ther. 333, 564–573 (2010).Crossref, Medline, CAS, Google Scholar
20 Mir SU, Ahmed IS, Arnold S, Craven RJ. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int. J. Cancer 131, E1–E9 (2012).Crossref, Medline, CAS, Google Scholar
21 Izzo NJ, Staniszewski A, To L et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS ONE 9, e111898 (2014). •• This work contains the first reports of sig-2R interacting with Abeta oligomers in Alzheimer's disease.Crossref, Medline, Google Scholar
22 Izzo NJ, Xu J, Zeng C et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS ONE 9, e111899 (2014). •• This paper provides support to sig-2R interacting with Abeta oligomers and has prompted the investigation of sig-2R antagonists in Alzheimer's disease.Crossref, Medline, Google Scholar
23 Abate C, Niso M, Infantino V, Menga A, Berardi F. Elements in support of the ‘non-identity’ of the PGRMC1 protein with the σ2 receptor. Eur. J. Pharmacol. 758, 16–23 (2015). •• This paper sheds the light on the nonidentity between progesterone receptor membrane component 1 and sig-2R prompting other studies that finally confirmed such misidentification.Crossref, Medline, CAS, Google Scholar
24 Chu UB, Mavlyutov TA, Chu ML et al. The sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes. EBioMedicine 2, 1806–1813 (2015).Crossref, Medline, Google Scholar
25 Pati ML, Groza D, Riganti C et al. Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1. Pharmacol. Res. 117, 67–74 (2017).Crossref, Medline, CAS, Google Scholar
26 Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the σ2 receptor. Proc. Natl Acad. Sci. USA 114, 7160–7165 (2017). •• This paper provides evidence of the identification of TMEM97 as sig-2R opening a new lines or research.Crossref, Medline, CAS, Google Scholar
27 Ebrahimi-Fakhari D Wahlster L Bartz F et al. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann–Pick type C1 disease cells. Hum. Mol. Genet. 25, 3588–3599 (2016).Crossref, Medline, CAS, Google Scholar
28 Moebius FF, Striessnig J, Glossmann H. The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends. Pharmacol. Sci. 18, 67–70 (1997).Crossref, Medline, CAS, Google Scholar
29 Mach RH, Zeng C, Hawkins WG. The σ2 receptor: a novel protein for the imaging and treatment of cancer. J. Med. Chem. 56, 7137–7160 (2013).Crossref, Medline, CAS, Google Scholar
30 Ding H, Gui XH, Lin XB et al. Prognostic value of MAC30 expression in human pure squamous cell carcinomas of the lung. Asian Pac. J. Cancer Prev. 17, 2705–2710 (2016).Medline, Google Scholar
31 Zhao ZR, Zhang LJ, HE XQ et al. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy 57, 394–401 (2011).Crossref, Medline, CAS, Google Scholar
32 Phase I Clinical Trial, ClinicalTrials.gov. Identifier: NCT02570997. A two-part, double-blind, placebo-controlled, Phase I study of the safety pharmacokinetics of single and multiple ascending doses of CT1812 in healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT02570997.Google Scholar
33 Phase I and II Clinical Trial, ClinicalTrials.gov. Identifier: NCT02907567. A randomized, double-blind, placebo-controlled, Phase I study of the safety & pharmacokinetics of two doses of CT1812 in subjects with mild to moderate Alzheimer's disease. https://clinicaltrials.gov/ct2/show/NCT02907567.Google Scholar
34 Abate C, Perrone R, Berardi F. Classes of sigma2 (σ2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity. Curr. Pharm. Des. 18, 938–949 (2012).Crossref, Medline, CAS, Google Scholar
35 Huang YS, Lu HL, Zhang LJ, Wu Z. Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med. Res. Rev. 34, 532–566 (2014).Crossref, Medline, CAS, Google Scholar
36 Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184: ligands with high σ2 receptor affinity and subtype selectivity. Eur. J. Pharmacol. 278, 257–260 (1995).Crossref, Medline, CAS, Google Scholar
37 Bertha CM, Mattson MV, Flippen-Anderson JL et al. A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl)morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of σ receptor ligands. J. Med. Chem. 37, 3163–3170 (1994).Crossref, Medline, CAS, Google Scholar
38 Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62, 313–322 (2002).Medline, CAS, Google Scholar
39 Gebreselassie D, Bowen WD. Sigma-2 are specifically localized to lipid refts in rat liver membranes. Eur. J. Pharmacol. 493, 19–28 (2004).Crossref, Medline, CAS, Google Scholar
40 Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 292, 900–911 (2000).Medline, CAS, Google Scholar
41 Perregaard J, Moltzen EK, Meier E, Sanchez C. σ Ligands with subnanomolar affinity and preference for the σ₂ binding site. 1. 3-(ω-Aminoalkyl)-1H-indoles. J. Med. Chem. 38, 1998–2008 (1995).Crossref, Medline, CAS, Google Scholar
42 Maier CA, Wunsch B. Novel spiropiperidines as higly potent and subtype selective σ-receptor ligands. part 1. J. Med. Chem. 45, 438–448 (2002).Crossref, Medline, CAS, Google Scholar
43 Maestrup EG, Wiese C, Schepmann D, Brust P, Wünsch B. Synthesis, pharmacological activity and structure affinity relationships of spirocyclic σ(1) receptor ligands with a (2-fluoroethyl) residue in 3-position. Bioorg. Med. Chem. 19, 393–405 (2011).Crossref, Medline, CAS, Google Scholar
44 Moltzen EK, Perregaard J, Meier E. σ Ligands with subnanomolar affinity and preference for the σ2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J. Med. Chem. 38, 2009–2017 (1995).Crossref, Medline, CAS, Google Scholar
45 Mach RH, Yang B, Wu L, Kuhner RJ, Whirrett BR, West T. Synthesis and sigma receptor binding affinities of 8-azabicyclo[3.2.1]octan-3-yl and 9-azabicyclo[3.3.1]nonao-3-yl phenylcarbamates. Med. Chem. Res. 10, 339–355 (2001).CAS, Google Scholar
46 Mach RH, Vangveravong S, Huang Y, Yang B, Blair JB, Wu L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as sigma-2 receptor ligands. Med. Chem. Res. 11, 380–398 (2003).Google Scholar
47 Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as σ₂ receptor ligands. Bioorg. Med. Chem. 14, 6988–6897 (2006).Crossref, Medline, CAS, Google Scholar
48 Chu W, Xu J, Dong Z et al. New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ₂ receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorg. Med. Chem. 17, 1222–1231 (2009).Crossref, Medline, CAS, Google Scholar
49 Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62, 313–322 (2002).Medline, CAS, Google Scholar
50 Kashiwagi H, McDunn JE, Simon PO et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol. Cancer 6, 48 (2007).Crossref, Medline, Google Scholar
51 Xu J, Tu Z, Jones LA, Wheeler KT, Mach RH. [³H]N-[4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. Eur. J. Pharmacol. 525, 8–17 (2005).Crossref, Medline, CAS, Google Scholar
52 Phase I Clinical Trial. ClinicalTrials.gov Identifier: NCT00968656. Assessment of cellular proliferation in tumors by positron emission tomography (PET) using [¹⁸F]ISO-1 (PET/CT) https://clinicaltrials.gov/ct2/show/NCT00968656.Google Scholar
53 Pilot study. ClinicalTrials.gov Identifier: NCT03057743. Imaging of in vivo sigma-2 receptor expression with 18F-ISO-1 positron emission tomography in metastatic breast cancer.Google Scholar
54 Phase I Clinical Trial. ClinicalTrials.gov Identifier: NCT02762110. Imaging of in vivo sigma-2 receptor expression with [18F]ISO-1 positron emission tomography (PET/CT) in primary breast cancer.Google Scholar
55 Phase I Clinical Trial. Clinical.Trials.gov Identifier: NCT02204202. Positron emission tomography assessment of acute lung transplant rejection.Google Scholar
56 Hornick JR, Xu J, Vangveravong S et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. Cancer 9, 298 (2010).Crossref, Medline, CAS, Google Scholar
57 Tu Z, Xu J, Jones LA et al. Fluorine-18 labeled benzamide analogs for imaging the sigma-2 receptor status of solid tumors with positron emission tomography. J. Med. Chem. 50, 3194–3204 (2007).Crossref, Medline, CAS, Google Scholar
58 Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and σ₂ receptor ligands. Bioorg. Med. Chem. 14, 195–202 (2004).Crossref, CAS, Google Scholar
59 Xu R, Lever JR, Lever SZ. Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for σ receptors. Bioorg. Med. Chem. Lett. 17, 2594–2597 (2007).Crossref, Medline, CAS, Google Scholar
60 Fan KF, Lever JR, Lever SZ. Effect of structural modification on amine portion of substituted aminobutyl-benzamides as ligands for bindng σ₁ and σ₂ receptors. Bioorg. Med. Chem. 19, 1852–1859 (2011).Crossref, Medline, CAS, Google Scholar
61 Berardi F, Abate C, Ferorelli S, Colabufo NA, Perrone R. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (σ₁) and sigma-2 (σ₂) receptor ligands: a review. Cent. Nerv. Syst. Agents Med. Chem. 9, 205–219 (2009).Crossref, Medline, CAS, Google Scholar
62 Berardi F, Ferorelli S, Abate C et al. 4-(Tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist σ2 activity. J. Med. Chem. 47, 2308–2317 (2004).Crossref, Medline, CAS, Google Scholar
63 Abate C, Selivanova SV, Müller A et al. Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the positron emission tomography (PET) imaging of σ2 receptors. Eur. J. Med. Chem. 69, 920–930 (2013).Crossref, Medline, CAS, Google Scholar
64 Niso M, Pati ML, Berardi F, Abate C. Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracer. RSC Adv. 6, 88508–88518 (2016).Crossref, CAS, Google Scholar
65 Kassiou M, Robert F, Dannals RF et al. Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorg. Med. Chem. 13, 3623–3626 (2005).Crossref, Medline, CAS, Google Scholar
66 Abate C, Niso M, Lacivita E, Mosier PD, Toscano A, Perrone R. Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers. J. Med. Chem. 54, 1022–1032 (2011).Crossref, Medline, CAS, Google Scholar
67 Selivanova SV, Toscano A, Abate C et al. Synthesis and pharmacological evaluation of ¹¹C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging. Nucl. Med. Biol. 42, 399–405 (2015).Crossref, Medline, CAS, Google Scholar
68 Berardi F, Abate C, Ferorelli S et al. Exploring the importance of piperazine N-atoms for σ2 receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28). J. Med. Chem. 52, 7817–7828 (2009).Crossref, Medline, CAS, Google Scholar
69 Abate C, Niso M, Contino M et al. 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: mixed σ and human Δ₈–Δ₇ sterol isomerase ligands with antiproliferative and p-Glycoprotein inhibitory activity. ChemMedChem 6, 73–80 (2011).Crossref, Medline, CAS, Google Scholar
70 Chen X, Cui MC, Deuther-Conrad W et al. Synthesis and biological evaluation of a novel [99m]Tc cyclopentadienyl tricarbonyl complex ([(Cp-R)[99mTc](CO)3]) for sigma-2 receptor tumor imaging. Bioorg. Med. Chem. Lett. 22, 6352–6357 (2012).Crossref, Medline, CAS, Google Scholar
71 Ferorelli S, Abate C, Colabufo NA et al. Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies. J. Med. Chem. 50, 4648–4655 (2007).Crossref, Medline, CAS, Google Scholar
72 Zeng C, McDonald ES, Mach RH. Molecular probes for imaging the sigma-2 receptor: in vitro and in vivo imaging studies. Handb. Exp. Pharmacol. 244, 309–330 (2017).Crossref, Medline, CAS, Google Scholar
73 Haller JL, Panyutin I, Chaudhry A, Zeng C, Mach RH, Frank JA. Sigma-2 receptor as potential indicator of stem cell differentiation. Mol. Imaging Biol. 14, 325–335 (2012).Crossref, Medline, Google Scholar
74 Zeng C, Garg N, Mach RH. The PGRMC1 protein level correlates with the binding activity of a sigma-2 fluorescent probe (SW120) in rat brain cells. Mol. Imaging Biol. 18, 172–179 (2016).Crossref, Medline, CAS, Google Scholar
75 Abate C, Hornick JR, Spitzer D et al. Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells. J. Med. Chem. 54, 5858–5867 (2011).Crossref, Medline, CAS, Google Scholar
76 Abate C, Niso M, Marottoli R et al. Novel derivatives of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with improved fluorescent and σ receptors binding properties. J. Med. Chem. 57, 3314–3323 (2014).Crossref, Medline, CAS, Google Scholar
77 Niso M, Riganti C, Pati ML, Ghigo D, Berardi F, Abate C. Novel and selective fluorescent σ2 -receptor ligand with a 3,4-dihydroisoquinolin-1-one scaffold: a tool to study σ2 receptors in living cells. ChemBioChem 16, 1078–1083 (2015).Crossref, Medline, CAS, Google Scholar
78 Spitzer D, Simon PO Jr, Kashiwagi H et al. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 72, 201–209 (2012).Crossref, Medline, CAS, Google Scholar
79 Ohman KA, Hashim YM, Vangveravong S et al. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget 7, 33529–33541 (2016).Crossref, Medline, Google Scholar
80 Zeng C, Vangveravong S, McDunn JE, Hawkins WG, Mach RH. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. Br. J. Cancer 109, 2368–2377 (2013).Crossref, Medline, CAS, Google Scholar
81 Garg G, Vangveravong S, Zeng C et al. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol. Cancer 13, 50 (2014).Crossref, Medline, Google Scholar
82 Hashim YM, Spitzer D, Vangveravong S et al. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol. Oncol. 8, 956–967 (2014).Crossref, Medline, CAS, Google Scholar
83 Makvandi M, Tilahun ED, Lieberman BP et al. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. Biochem. Biophys. Res. Commun. 467, 1070–1075 (2015).Crossref, Medline, CAS, Google Scholar
84 Hall MD, Brimacombe KR, Varonka MS et al. Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J. Med. Chem. 54, 5878–5889 (2011).Crossref, Medline, CAS, Google Scholar
85 Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98–105 (2012).Crossref, Medline, CAS, Google Scholar
86 Cassano G, Gasparre G, Niso M, Contino M, Scalera V, Colabufo NA. F281, synthetic agonist of the sigma-2 receptor, induces Ca(2+) efflux from the endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium 45, 340–345 (2009).Crossref, Medline, CAS, Google Scholar
87 Abate C, Ferorelli S, Contino M et al. Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers. Eur. J. Med. Chem. 46, 4733–4741 (2011).Crossref, Medline, CAS, Google Scholar
88 Niso M, Abate C, Riganti C. Collateral sensitivity of sigma-2 receptor ligands: potentials in the treatment of multidrug resistant tumors. Recept. Clin. Investig. 1, 208–216 (2014).Google Scholar
89 Pati ML, Niso M, Ferorelli S, Abate C, Berardi F. Novel metal chelators thiosemicarbazones with activity at the σ2 receptors and P-glycoprotein: an innovative strategy for resistant tumors treatment. RSC Adv. 5, 103131–103146 (2015).Crossref, CAS, Google Scholar
90 Pati ML, Niso M, Spitzer D et al. Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: in vitro and in vivo activity in pancreatic tumors. Eur. J. Med. Chem. 144, 359–371 (2018).Crossref, Medline, CAS, Google Scholar
91 Mésangeau C, Amata E, Alsharif W et al. Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. Eur. J. Med. Chem. 46, 5154–5161 (2011).Crossref, Medline, CAS, Google Scholar
92 Amata E, Dichiara M, Arena E et al. Novel sigma receptor ligand-nitric oxide photodonors: molecular hybrids for double-targeted antiproliferative effect. J. Med. Chem. 60, 9531–9544 (2017).Crossref, Medline, CAS, Google Scholar
93 van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RA. Potential applications for sigma receptor ligands in cancer diagnosis and therapy. Biochim. Biophys. Acta. 1848, 2703–2714 (2015).Crossref, Medline, CAS, Google Scholar
94 Ramzy L, Nasr M, Metwally AA, Awad GAS. Cancer nanotheranostics: a review of the role of conjugated ligands for overexpressed receptors. Eur. J. Pharm. Sci. 104, 273–292 (2017).Crossref, Medline, CAS, Google Scholar
95 Banerjee R 1, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer. 112, 693–700 (2004).Crossref, Medline, CAS, Google Scholar
96 Dayan G, Lupien M, Auger A et al. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha. Mol. Pharmacol. 70, 579–588 (2006).Crossref, Medline, CAS, Google Scholar
97 Yang Y, Hu Y, Wang Y, Li J, Liu F, Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small-cell lung cancer. Mol. Pharmacol. 9, 2280–2289 (2012).Crossref, CAS, Google Scholar
98 Yang Y, Li J, Liu F, Huang L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol. Ther. 20, 609–615 (2012).Crossref, Medline, CAS, Google Scholar
99 Guo J, Ogier JR, Desgranges S, Darcy R, O'Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 33, 7775–7784 (2012).Crossref, Medline, CAS, Google Scholar
100 Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control Release 157, 279–286 (2012).Crossref, Medline, CAS, Google Scholar
101 Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942–946 (2008).Crossref, Medline, CAS, Google Scholar
102 Mukherjee A, Prasad TK, Rao NM, Banerjee R. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells. J. Biol. Chem. 280, 15619–15627 (2005).Crossref, Medline, CAS, Google Scholar
103 Zhang Y, Huang Y, Zhang P, Gao X, Gibbs RB, Li S. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int. J. Nanomedicine 7, 4473–4485 (2012).Medline, CAS, Google Scholar
104 Wang Y, Xu J, Xia X et al. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. Nanoscale 4, 421–424 (2012).Crossref, Medline, CAS, Google Scholar
105 Sun T, Wang Y, Wang Y et al. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. Adv. Healthc. Mater. 3, 1283–1291 (2014).Crossref, Medline, CAS, Google Scholar
106 Ludwig JM, Gai Y, Sun L, Xiang G, Zeng D, Kim HS. SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment – an in vitro evaluation. Mol. Oncol. 10, 1133–1145 (2016).Crossref, Medline, CAS, Google Scholar
107 Pati ML, Fanizza E, Hager S et al. Quantum dot based luminescent nanoprobes for sigma-2 receptor imaging. Mol. Pharm. 15, 458–471 (2018).Crossref, Medline, CAS, Google Scholar

Vol. 10, No. 16

Supplemental Materials

Metrics

Downloaded 371 times

History

Received 9 March 2018

Accepted 31 May 2018

Published online 3 July 2018

Published in print August 2018

Information

Keywords

Supplementary data

See online at: https://www.future-science.com/doi/10.4155/fmc-20187-0072

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations

Abstract

References